Non-resolving ARDS
Conditions
Brief summary
[68Ga]FAPI uptake related to 28 days mortality, [68Ga]FAPI uptake related to ICU stay, [68Ga]FAPI uptake related to VFD-28
Detailed description
The relationship between pulmonary fibroblast activity, measured by FAPI-PET to clinically determined parameters of respiratory state (i.e. PEEP, Ppeak, lung compliance, driving pressure, mechanical power) and plasma markers of extracellular matrix and inflammation (e.g. IL-8/IL-6/TNFalpha and ProC3, C3M).2 Furthermore, we will perform a BAL to collect respiratory cytology and determine cellular phenotypes using scRNA., Evaluating PET/CT procedure using evaluation form and adverse event registration.
Interventions
DRUG[68Ga]FAPI-46
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| [68Ga]FAPI uptake related to 28 days mortality, [68Ga]FAPI uptake related to ICU stay, [68Ga]FAPI uptake related to VFD-28 | — |
Secondary
| Measure | Time frame |
|---|---|
| The relationship between pulmonary fibroblast activity, measured by FAPI-PET to clinically determined parameters of respiratory state (i.e. PEEP, Ppeak, lung compliance, driving pressure, mechanical power) and plasma markers of extracellular matrix and inflammation (e.g. IL-8/IL-6/TNFalpha and ProC3, C3M).2 Furthermore, we will perform a BAL to collect respiratory cytology and determine cellular phenotypes using scRNA., Evaluating PET/CT procedure using evaluation form and adverse event registration. | — |
Countries
Netherlands
Outcome results
None listed